Abstract
Background
It is important to examine how a usual drug dose is established in Japan and other countries, and to evaluate that on the basis of pharmacokinetic and pharmacodynamic properties. In the present study, we examined the contributions of area under the curve (AUC) ratio and other factors on differences of usual dose between Japan and the United States.
Methods
We examined drugs approved from January 2008 to January 2011 in Japan and collected related information. For the usual dose set for the same indication in both countries, we compared the maintenance dose values between the countries. We also examined the relationships of AUC ratio and difference of usual dose in both countries.
Results
Our results clarified that the usual dose for the same indication is comparable between Japan and the United States for 68.75% of the examined drugs, while that for 31.25% is different. Moreover, among products with different approved doses, the dosage was set higher in the United States for 18.75% and higher in Japan for 12.50%. Our findings indicate that the difference in dose between the countries is associated with AUC ratio for 82.1% and by factors other than AUC ratio for 17.9% of the examined medications.
Conclusions
The approved dose varies between the countries for about one-third of products commonly used. Additionally, it was clarified that not only AUC ratio but also other factors are involved in dosage differences. The present results provide useful information for analysis of factors related to the different usual doses between countries.
Similar content being viewed by others
References
Kenmotsu H, Tanigawara Y. Pharmacokinetics, dynamics and toxicity of docetaxel: why the Japanese dose differs from the Western dose. Cancer Sci. 2015;106(5):497–504.
Arnold FL, Fukunaga S, Kusama M, Matsuki N, Ono S. Assessment of factors associated with dose differences between Japan and the United States. Clin Pharmacol Ther. 2014;95(5): 542–549.
Arnold FL, Kusama M, Ono S. Exploring differences in drug doses between Japan and Western countries. Clin Pharmacol Ther. 2010; 87(6):714–720.
Fukunaga S, Kusama M, Arnold FL, Ono S. Ethnic differences in pharmacokinetics in new drug applications and approved doses in Japan. J Clin Pharmacol. 2011;51(8):1237–1240.
Ministry of Health, Labour and Welfare. Notification No. 672 issued by the Director of Evaluation and Licensing Division, Pharmaceutical Affairs Bureau. https://www.pmda.go.jp/files/000156571.pdf. Accessed November 24, 2017.
Ministry of Health, Labour and Welfare. Notification No. 0928010 issued by the Director of Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau. http://www.pmda.go.jp/files/000157900.pdf#page=11. Accessed November 24, 2017.
Pharmaceuticals and Medical Devices Agency. http://www.pmda.go.jp/PmdaSearch/iyakuSearch/. Accessed November 24, 2017.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Takayanagi, R., Endo, Y., Kimura, K. et al. Comparisons of Usual Dose of Pharmaceutical Products Used in Japan and United States: Can Differences Be Explained by Pharmacokinetics Alone?. Ther Innov Regul Sci 53, 684–690 (2019). https://doi.org/10.1177/2168479018805432
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1177/2168479018805432